BACKGROUND: Evidence suggests that insulin-like growth factor 2 messenger RNA
binding protein 3 (IGF2BP3, also known as IMP3) represents a promising cancer biomarker …

Abstract N6-Methyladenosine (m6A) modification is the most abundant RNA modification in
eukaryotic cells. IGF2BP3, a well-known m6A reader, is deregulated in many cancers, but its …

The post-transcriptional control of gene expression mediated by RNA-binding proteins
(RBPs), long non-coding RNAs (lncRNAs) as well as miRNAs is essential to determine …

Previous literatures reported insulin‐like growth factor‐2 messenger RNA‐binding protein 3
(IGF2BP3) is a poor prognostic marker for colorectal cancer (CRC) patients. However, basic …

Background The survival of pancreatic cancer patients remains poor. However, the
underlying molecular mechanism and new therapeutic target of pancreatic cancer are still …

Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), an RNA-binding protein, is
associated with tumorigenesis and progression. However, the exact molecular mechanisms …

Emerging discoveries of dynamic and reversible N6-methyladenosine (m6A) modification on
RNA in mammals have revealed the key roles of the modification in human tumorigenesis …

The gene encoding the Insulin-like Growth Factor 2 mRNA binding protein 2/IMP2 is
amplified and overexpressed in many human cancers, accompanied by a poorer prognosis …

Background Lymph node metastasis is the main cause of poor prognosis of head and neck
squamous carcinoma (HNSCC) patients. N6-methyladenosine (m6A) RNA modification is …

The oncofetal IGF2 mRNA binding proteins (IGF2BPs) are upregulated in most cancers but
their paralogue-specific roles in tumor cells remain poorly understood. In a panel of five …